NO20065671L - Fremgangsmater for redusering av biofilmdannelse i infeksiose bakterier. - Google Patents

Fremgangsmater for redusering av biofilmdannelse i infeksiose bakterier.

Info

Publication number
NO20065671L
NO20065671L NO20065671A NO20065671A NO20065671L NO 20065671 L NO20065671 L NO 20065671L NO 20065671 A NO20065671 A NO 20065671A NO 20065671 A NO20065671 A NO 20065671A NO 20065671 L NO20065671 L NO 20065671L
Authority
NO
Norway
Prior art keywords
biofilm formation
methods
infectious bacteria
reducing biofilm
bacteria
Prior art date
Application number
NO20065671A
Other languages
English (en)
Inventor
Keith Alan Charlton
Andrew Justin Radcliff Porter
Lorna Thornthwaite
Original Assignee
Haptogen Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Haptogen Ltd filed Critical Haptogen Ltd
Publication of NO20065671L publication Critical patent/NO20065671L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/40—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum bacterial
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1203—Gram-negative bacteria
    • C07K16/1214—Pseudomonadaceae (F)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Foreliggende oppfinnelse fremskaffer fremgangsmåter for forhindring eller inhibering av biofilmdannelse av en populasjon av bakterier, hvor nevnte fremgangsmåte omfatter administrasjonen til populasjonen av et antistoff for et lakton eller lakton-avledet signalmolekyl utskilt av bakterier. Foreliggende oppfinnelse fremskaffer derfor fremgangsmåter for behandlingen av bakteriell infeksjon ved at biofilmdannelse blir forhindret eller hemmet.
NO20065671A 2004-05-15 2006-12-08 Fremgangsmater for redusering av biofilmdannelse i infeksiose bakterier. NO20065671L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0410958.3A GB0410958D0 (en) 2004-05-15 2004-05-15 Methods for reducing biofilm formation in infectious bacteria
PCT/GB2005/001843 WO2005111080A2 (en) 2004-05-15 2005-05-13 Methods for reducing biofilm formation in infectious bacteria

Publications (1)

Publication Number Publication Date
NO20065671L true NO20065671L (no) 2006-12-08

Family

ID=32527168

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20065671A NO20065671L (no) 2004-05-15 2006-12-08 Fremgangsmater for redusering av biofilmdannelse i infeksiose bakterier.

Country Status (12)

Country Link
US (1) US20090117109A1 (no)
EP (2) EP1749031B1 (no)
JP (2) JP2008502710A (no)
KR (2) KR20070038464A (no)
CN (1) CN1984929A (no)
AU (1) AU2005243459B2 (no)
CA (1) CA2566588A1 (no)
DK (1) DK1749031T3 (no)
ES (1) ES2427933T3 (no)
GB (1) GB0410958D0 (no)
NO (1) NO20065671L (no)
WO (1) WO2005111080A2 (no)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100602A1 (en) * 2008-03-12 2009-09-16 QuoNova Europe GmbH Method and compositions suitable for treatment of wounds
KR100868574B1 (ko) * 2008-03-17 2008-11-13 한국광해관리공단 토양 입자 표면에 형성된 바이오필름의 함량 측정 방법
PT2411410E (pt) * 2009-03-27 2015-10-09 Gojo Ind Inc Composições e métodos para screening e utilização de compostos que antagonizam interações esporo-superfície
EP2447221A4 (en) * 2009-06-22 2013-01-02 Sumitomo Heavy Industries PROCESS FOR TREATING WASTE WATER CONTAINING AMMONIACAL NITROGEN
WO2012058531A2 (en) * 2010-10-29 2012-05-03 North Carolina State University Modulation of response regulators by imidazole derivatives
WO2012084272A1 (en) * 2010-12-23 2012-06-28 Intercell Ag Oprf/i agents and their use in hospitalized and other patients
JP2014506923A (ja) 2011-03-01 2014-03-20 クオラム イノベーションズ リミテッド ライアビリティ カンパニー 病原性バイオフィルムと関連した状態を治療するための物質および方法
US9387189B2 (en) 2013-05-22 2016-07-12 Professional Compounding Centers Of America (Pcca) Antibiotic composition comprising a chemotactic agent and a nutrient dispersion
NO342374B1 (en) * 2016-07-08 2018-05-14 Inhibio As Compounds and compositions for biofilm prevention
KR102305308B1 (ko) * 2019-06-12 2021-09-27 서정옥 좌석용 헤드레스트 목베개
US20240123101A1 (en) * 2022-10-13 2024-04-18 Hossam Abdel Salam El Sayed Mohamed System and method for prevention of corrosive biofilm formation in petroleum holding or carrying structures

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5254671A (en) * 1990-04-27 1993-10-19 Tanox Biosystems, Inc. Extracellular segments of human e immunoglobulin anchoring peptides and antibodies specific therefor
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU753329C (en) * 1997-06-18 2003-05-15 Montana State University Homoserine lactones biofilm regulating compounds and their methods of use
US6395282B1 (en) * 1998-04-16 2002-05-28 University Of Rochester Immunogenic conjugates of Gram-negative bacterial autoinducer molecules
WO1999061021A1 (en) * 1998-05-26 1999-12-02 Shionogi & Co., Ltd. Drug-sensitivity recovering agents for resistant pathogenic microorganisms
US6090388A (en) * 1998-06-20 2000-07-18 United Biomedical Inc. Peptide composition for prevention and treatment of HIV infection and immune disorders
DE69930166T2 (de) 1998-11-25 2006-12-14 MCW Research Foundation, Inc., Milwaukee Verfahren und zusammensetzungen für impfung mit dem pseudomonas aeruginosa v-antigen
GB9924195D0 (en) 1999-10-13 1999-12-15 Univ Nottingham N-Acyl homoserine lactones for the treatment of cardiac tachyarrhythmias Ischaemic heart disease or congestive heart failure
GB0007588D0 (en) 2000-03-30 2000-05-17 Univ Nottingham N-Acyl homoserine lactones
US6703513B1 (en) * 2000-06-02 2004-03-09 K-Quay Enterprises Llc Production and use of derivatized homoserine lactones
ATE550036T1 (de) * 2002-08-13 2012-04-15 Haptogen Ltd Verfahren zur behandlung einer bakteriellen infektionskrankheit mittels antikörpern gegen laktone oder gegen von laktonen abgeleiteten signalmolekülen
GB0407008D0 (en) * 2004-03-27 2004-04-28 Haptogen Ltd Methods for inducing rapid cell death (autolysis) in infectious bacteria

Also Published As

Publication number Publication date
EP2281839A2 (en) 2011-02-09
JP2008502710A (ja) 2008-01-31
CA2566588A1 (en) 2005-11-24
KR20070038464A (ko) 2007-04-10
WO2005111080A2 (en) 2005-11-24
EP2281839A3 (en) 2013-02-27
KR20130036365A (ko) 2013-04-11
EP1749031B1 (en) 2013-07-17
JP2011042651A (ja) 2011-03-03
ES2427933T3 (es) 2013-11-04
GB0410958D0 (en) 2004-06-16
AU2005243459B2 (en) 2011-11-03
AU2005243459A1 (en) 2005-11-24
US20090117109A1 (en) 2009-05-07
DK1749031T3 (da) 2013-09-23
AU2005243459A2 (en) 2005-11-24
EP1749031A2 (en) 2007-02-07
WO2005111080A3 (en) 2006-01-12
CN1984929A (zh) 2007-06-20

Similar Documents

Publication Publication Date Title
EA200701822A1 (ru) Пиразолилкарбоксанилиды
EA201100094A1 (ru) Тиадиазолилоксифениламидины и их применение в качестве фунгицидов
WO2008115281A3 (en) Compounds for treating viral infections
EA200802213A1 (ru) Способы лечения заболеваний крови
SG159542A1 (en) Compositions against sars-coronavirus and uses thereof
EA201000903A1 (ru) Антитела к pcrv-антигену pseudomonas aeruginosa
UA110199C2 (xx) Тверда дисперсія рифаксиміну
MXPA05009352A (es) Metodos y composiciones para tratamiento y prevencion de staphylococcus y otras infecciones bacterianas.
CY1111587T1 (el) Αναεροβιος καθαρισμος λυματων
WO2005072826A3 (en) Compositions and use of tyrosine kinase inhibitors to treat pathogenic infection
EA201000383A1 (ru) Способ ингибирования клостридиум диффициле введением оритаванцина
NO20065671L (no) Fremgangsmater for redusering av biofilmdannelse i infeksiose bakterier.
ATE463579T1 (de) Verfahren zur herstellung einer l-aminosäure unter verwendung eines bakteriums der familie enterobacteriaceae mit abgeschwächter expression des yafa-gens
ATE469976T1 (de) Mikrobielle vitamin-c-produktion
MX2008016269A (es) Fermentacion y purificacion de cromoproteinas actinomadura y especies relacionadas.
WO2006120563A3 (en) Antibacterial agents
DE602005015963D1 (de) Estergebundene makrolide, die sich für die behandlung von mikrobiellen infektionen eignen
ATE444749T1 (de) Benzothiazolium verbindungen zur verwendung in methoden zur hemmung der no produktion und von tnf alpha und zur behandlung von coronavirus infektionen
GT200500308A (es) Nonadepsipeptidos acilados ii
DE602007008100D1 (de) Cellulosesulfat zur behandlung von rhinovirus-infektionen
AR057641A1 (es) Compuestos 5- nitro - nucleosidos para tratar infecciones virales
TW200716162A (en) Use of bovine lactoferrin in the manufacture of a medicament for inhibiting the growth of bacteria
TN2009000374A1 (fr) Macrolides a base d'erythromycine
DK1817326T3 (da) Industriel fremgangsmåde til fremstilling af 17-hydroxy-6-beta, 7-beta, 15-beta, 16-beta-bismethylen-3-oxo-17-alpha-pregn-4-en-21-carboxylsyre-gamma-lacton og nøglemellemprodukter for denne fremgangsmåde
HRP20051005A2 (en) Process for the preparation of nonpeptide substituted spirobenzoazepine derivatives